MARKET ANALYSIS

An absorbable antibacterial envelope is a medical device that lowers the risk of infection among cardiac patients with implants like pacemaker or defibrillator placement. Antibiotics like minocycline and rifampin are included in the device bio-absorbable polymer matrix and delivered gradually over several weeks after implantation. During the process, an absorbable antibacterial envelope is placed around the implantable device in order to provide a physical barrier between the device and surrounding tissue. Patients with underlying medical conditions and low immunity are prone to various infections caused by the cardiac implantation that can further complicate the patient's conditions. The use of envelope can reduce the prevalence of these infections, improving patient outcomes and reducing the overall healthcare expenses.

GROWTH DRIVERS AND CHALLENGES

The market for absorbable antibacterial envelopes is anticipating growth due to various driving factors such as these envelopes are designed to reduce the risk of surgical site infections (SSIs) by providing a localised antimicrobial barrier at the surgical site. Additionally, rising number of surgical procedures and increasing focus on infection control and patient safety, as SSIs can lead to complications, prolonged hospital stays, and increased healthcare costs. According to NCBI, every year around 1.5 million patients receive cardiac implantable electrical devices (CIED) globally. From which 1% to 4% of these patients developing infections, resulting in significant impacts on mortality, quality of life, healthcare utilisation, and cost to global healthcare systems. Moreover, Implant site hematoma, which is localised bleeding outside of the blood vessels, is known as complication of CIED procedures and can lead to device-related infections. Previous randomized controlled studies found more than seven-fold risk of subsequent serious device-related infections in patients who acquire a hematoma. Furthermore, as healthcare providers and regulatory bodies prioritize infection prevention that can create demand for absorbable antibacterial envelopes in the near future.

REPORT SEGMENTATION AND SCOPE

The "Global absorbable antibacterial envelope market Analysis to 2030" is a specialized and in-depth study focusing on the global absorbable antibacterial envelope market trends and growth opportunities. The report aims to provide an overview of the global absorbable antibacterial envelope market with detailed market segmentation by application, end user, and geography. The global absorbable antibacterial envelope market has witnessed high growth over the recent past and is expected to continue this trend during the forecast period. The report provides key statistics on the uses of absorbable antibacterial envelope worldwide and their demand in major regions and countries. In addition, the report provides a qualitative assessment of various factors affecting the absorbable antibacterial envelope market performance in major regions and countries. The report also includes a comprehensive analysis of the leading absorbable antibacterial envelope market players and their key strategic developments. Several analyses on the market dynamics are also included to help identify the key driving factors, market trends, and lucrative absorbable antibacterial envelope market opportunities that would, in turn, aid in identifying the major revenue pockets.

Further, ecosystem analysis and Porter's five forces analysis provide a 360-degree view of the global absorbable antibacterial envelope market. This helps understand the entire supply chain and various market absorbable antibacterial envelope growth factors.

SEGMENTAL ANALYSIS

The global absorbable antibacterial envelope market is segmented based application, end user, and geography. Based on application, the absorbable antibacterial envelope market is segmented as, cardiac resynchronization therapy defibrillator (CRT-D), implantable cardioverter defibrillator (ICD), and cardiac resynchronization therapy pacemaker (CRT-P). Cardiac resynchronization therapy defibrillator (CRT-D) segment is leading the market with the highest market share and is projected to grow significantly and dominate the global market during the forecast period. Based on end-user the absorbable antibacterial envelope market size is classified into hospitals, ambulatory surgical centres (ASCs), and others. The hospitals segment is expected to have the largest market share and the fastest rate of expansion, owing to increase in adoption of absorbable antibacterial envelope in cardiac implantable devices across the world.

REGIONAL ANALYSIS

The report provides a detailed overview of the global absorbable antibacterial envelope market with respect to five major regions namely, North America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA) and South & Central America. North America is estimated to account for a significant absorbable antibacterial envelope market share globally. In North America, market for absorbable antibacterial envelope is being driven by a various factor, such as increasing prevalence of cardiovascular disorders. The World Health Organisation (WHO) estimates that four out of every five deaths from cardiovascular diseases are attributable to cardiovascular disorders, such as heart attacks and strokes. The prevalence of cardiovascular diseases has increased in emerging countries as a result of changing lifestyles, an increase in the prevalence of diabetes, pre-diabetes, and others. The increasing patient population with cardiovascular problems will propel market growth in upcoming years. However, Asia Pacific is expected to grow significantly owing to the increase in research and development activities, technological advancements, and modernization of healthcare practices.

INDUSTRY DEVELOPMENTS AND FUTURE OPPORTUNITIES

Partnership, acquisitions and new product launches were found to be the major strategies adopted by the players operating in the global absorbable antibacterial envelope market.

In February 2021, Medtronic launched the TYRX absorbable antibacterial envelope, a single-use antibacterial envelope designed to alleviate a cardiac implantable electronic device (CIED) or implanted neurostimulator while releasing antimicrobial agents over a minimum of seven days. The TYRX Envelope retains the CIED device and is fully absorbed by the body about nine weeks after implantation. It is made of a multifilament, knitted, absorbable mesh. Any implantable defibrillator, pacemaker, or neurostimulator may be used with it.

In April 2022, Aziyo Biologics, Inc. has filed a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for CanGaroo RM antibacterial envelope, its next-generation biomaterial envelope for use with implantable electronic devices (IED). Aziyo Biologics is a commercial-stage regenerative medicine firm dedicated to developing the following line of distinctive products and enhancing surgical patient outcomes.

IMPACT OF COVID/IMPACT OF GEOPOLITICAL SCENARIO/IMPACT OF RECESSION

The covid-19 pandemic led to a decline in the progress of many industries across the globe. The market for absorbable antimicrobial envelopes has been impacted by the COVID-19 epidemic both directly and indirectly. The pandemic's direct effect has increased the significance of infection control procedures in healthcare facilities. Hospitals and healthcare facilities have been more attentive in putting infection control measures into place in order to prevent the spread of COVID-19 infection. The increased emphasis on infection control may have led to a greater demand for products like absorbable antimicrobial envelopes, which can help mitigate the risk of infections associated with medical devices. On the other hand, the pandemic has also caused disruptions in the healthcare industry, which could indirectly affect the absorbable antimicrobial envelope market. R&D efforts are also delayed or redirected towards addressing the urgent needs of the pandemic. Conversely, the absorbable antibacterial envelope market is growing after the significant efforts taken by market stakeholders and healthcare practitioners to manage the disrupted supply chain. Moreover, in 2021, the launch of vaccines controlled the infection, which led to the ease in government restrictions and the production of absorbable antibacterial envelope on a large scale. This further helps normalize overall absorbable antibacterial envelope market growth with a slight negative effect during the pandemic.

COMPETITIVE LANDSCAPE AND KEY COMPANIES

Some of the key players operating in the absorbable antibacterial envelope market include Aziyo Biologics and Medtronic.

Access Data

Have a question?

Mrinal

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

  Speak to Analyst

Access Data